The Biotech Spotlight Taps (Nasdaq: MDCX) For A Top Watchlist Spot (5 Potential Catalysts)

In the rapidly evolving landscape of life sciences

*Disseminated on behalf of Medicus Pharma Ltd. The Biotech Spotlight Taps (Nasdaq: MDCX) For A Top Watchlist Spot (5 Potential Catalysts) July 7th Greetings Readers, In the rapidly evolving landscape of life sciences, a select group of companies is capturing attention for their commitment to advancing novel therapies that address significant unmet medical needs. One company's wholly owned subsidiary is actively developing a non-invasive, dissolvable microneedle patch designed to deliver chemotherapeutic agents directly to tumor sites, aiming to transform the treatment paradigm for skin cancers such as basal cell carcinoma. This approach, currently undergoing rigorous clinical evaluation in both the United States and the United Arab Emirates, holds the potential to disrupt traditional cancer care by offering less invasive, more patient-friendly alternatives to surgery or systemic therapies. Beyond dermatological applications, this company is expanding its reach through strategic acquisitions, including a late-stage UK-based biotech focused on next-generation therapies for advanced prostate conditions. Such moves signal a broader ambition to impact multiple therapeutic areas, particularly those with high unmet need and opp's for improved safety and efficacy. By leveraging a collaborative, thesis-driven process and a robust network within the industry, this company is positioning itself to accelerate the clinical development and commercialization of disruptive therapeutic assets. As the global biotech market continues its rapid expansion, close attention to these types of developments is warranted, given their potential to reshape standards of care across both human and veterinary medicine. Plus, with a low float of fewer than 3Mn shares, two analyst targets suggesting significant upside potential, and a definitive agreement in place working towards a momentous acquisition, there's little doubt why I've got my radar fixated on this new Nasdaq profile. Consider turning your full attention to: *Medicus Pharma Ltd. (Nasdaq: MDCX)* Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. The company is actively engaged in multiple countries, spread over three continents. And based on several potential catalysts, (Nasdaq: MDCX) has pushed its way to the top of my watchlist. Take a look: No. 1 - A Low Float Could Create The Environment For Heightened Volatility. No. 2 - A Definitive Agreement Moves Medicus Pharma A Step Closer To A Game-Changing Acquisition. No. 3 - A Pair Of Analyst Targets Suggest Major Upside Potential (Triple-Digit!). No. 4 - Medicus Adds New COO As Company Ramps Up Active Engagements Across 3 Continents. No. 5 - A Potential $250Mn Market Could Be Nearing Disruption As Medicus Announces Submission To The FDA. But more on those in a second... Company Breakdown - Medicus Pharma Ltd. (Nasdaq: MDCX) Medicus Pharma Ltd. specializes in rapidly moving forward the clinical development of cutting-edge therapeutic solutions within the biotech and life sciences sector. About SkinJect - Medicus Pharma's (Nasdaq: MDCX) Wholly Owned Subsidiary A novel non-invasive regimen to treat skin cancer; especially Basal Cell Carcinoma. SkinJect Inc. is a development stage biotechnology life sciences company focused on commercializing novel treatment for non-melanoma skin cancer, especially basal cell carcinoma, using a patented dissolvable doxorubicincontaining microneedle arrays (D-MNA). D-MNA delivers the chemotherapeutic agent transdermally at the site of the lesion to eradicate tumor cells. The relevant US Patents were granted to University of Pittsburgh and Carnegie Mellon University in 2018. SkinJect Inc. secured exclusive worldwide development and commercialization rights from University of Pittsburgh and Carnegie Mellon University in April 2016. The company attempts to provide an alternative to an invasive, painful, but effective treatment commonly called Mohs Surgery, by providing an efficacious, painless and easy to administer treatment in an office setting. SkinJect Inc. has completed a Phase I study in March 2021 for participants with superficial and nodular Basal Cell Carcinoma (BCC). In January 2024 a Phase 2 IND clinical protocol was submitted to the FDA for a randomized, controlled, double-blind, multicenter study that is expected to randomize up to 60 patients. Patient recruitment began in August 2024 in 9 sites across the United States. A positively trending interim analysis in March 2025 showed more than 60% complete clinical response. In April 2025, IRB approved an increase in the number of patients from 60 to 90. SkinJect Clinical Development Outlook The SkinJect Value Proposition 1. Innovative Microneedle Patch Technology: The company aims to provide an alternative to an invasive, painful, but effective treatment commonly called Mohs Surgery, by providing an efficacious, painless and easy to administer treatment in an office setting. Patented technology for non-invasively treating skin cancer using cellulose-based microneedles to deliver cancer drugs directly to the tumor site Exclusive worldwide development and commercialization rights from University of Pittsburgh and Carnegie Mellon University in April 2016. 2. Market Potential: BCC is the most common and fastest-growing cancer globally. >US$15Bn market for skin cancer treatments in North America by 2030. (1) Potential for further market expansion and penetration by SkinJect’s novel treatment approach. 3. Positive Clinical Trial Results: Phase 1 trial completed March 2021, demonstrating safety and tolerability. In Q1 2024 a Phase 2 IND clinical protocol was submitted to the FDA for a randomized, controlled, double-blind, multicenter study. In Q3 2024 Phase 2 enrollment began. In Q1 2025 conducted interim analysis after 50% patient recruitment. In Q2 2025, IRB approved to increase number of patients from 60 to 90. 4. Seasoned Leadership and Board: Management team with public company experience. Board includes industry veterans and experts in oncology and drug development. Grab Key Sources: MDCX Presentation. MDCX Website. ----- And as I mentioned previously, (Nasdaq: MDCX) has several potential catalysts that could generate breakout buzz. Check them out: No. 1 MDCX Potential Catalyst - A Low Float Could Create The Environment For Heightened Volatility. According to info from the Finviz website, MDCX has a fairly low float. The website reports this profile to have roughly 2.34Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. If positive company news appears in the midway part of 2025, could it provide a breakout spark? ----- No. 2 MDCX Potential Catalyst - A Definitive Agreement Moves Medicus Pharma A Step Closer To A Game-Changing Acquisition. Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK Antev Shareholders to Receive Aggregate ~17% Equity Stake in Medicus plus US$65Mn in Contingent Payments Philadelphia, Pennsylvania--(Newsfile Corp. - June 30, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus") and Antev Ltd. ("Antev"), a UK-based clinical-stage drug development company, announced today that they have entered into a definitive agreement dated June 29, 2025 (the "Definitive Agreement") pursuant to which Medicus has agreed to acquire all of the issued and outstanding shares of Antev (the "Antev Shares") on a share exchange basis (the "Transaction"). Subject to the closing conditions noted in the Definitive Agreement, Medicus will acquire all issued and outstanding Antev Shares, on a fully diluted basis, in exchange for 2,666,600 (or approximately 17% in aggregate) of the issued and outstanding Medicus common shares (the "Consideration Shares"). ... The Transaction is expected to close before the end of August 2025, subject to the fulfillment of certain closing conditions, including obtaining Antev shareholder approval and other applicable corporate, regulatory and third-party approvals. No assurances can be given that the parties will successfully close the Transaction on the terms or timeframe currently contemplated or at all. Antev is a clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to enlarged prostate. Antev Acute Urinary Retention (AUR) Indication: Teverelix is aiming to be the first-in-class indication product for preventing recurrence of acute urinary retention (AURr) in males 45 years or older, who suffer from prostate enlargement. Antev has a US Food and Drug Administration (FDA) approved phase 2b study designed to randomize 390 men after a successful trial without catheterization (TWOC). 85% of nearly one million (1M) annual AUR episodes in the US occur in Men 60+ who suffer from enlarged prostate that manifests with age and frequently is followed by a recurrent episode within 6 months for approximately 30% of men, presenting a potential market opportunity of more than US $2Bn annually. Antev planned Phase 2b Study Design in Acute Urinary Retention: Randomized controlled double blinded study in 390 men after a successful TWOC in 60-70 sites in United States (US) and European Union (EU). The participants shall receive either single intramuscular (IM) or subcutaneous (SC) injection (90mg or 120mg) or placebo in addition to standard therapy. Primary endpoint is a composite of AURr, need for surgery or poor urinary flow metrics in the first 28 weeks plus 24 weeks follow up. Antev High Cardiovascular (CV) Risk Advanced Prostate Cancer (APC) indication: Teverelix is aiming to be the best-in-class indication product for hormone therapy for advanced prostate cancer (APC) patients with increased CV risk. Antev has a US Food and Drug Administration (FDA) approved phase 2b open label study designed to recruit 40 men with advanced prostate cancer. Antev is targeting a niche in patients with increased CV risk, aiming to provide an androgen deprivation therapy (ADT) option with potentially lower cardiac toxicity than conventional GnRH agonists. If approved, Teverelix could become the first hormone therapy labeled specifically for treating prostate cancer in patients with a history of cardiovascular disease. 300,000 to 500,000 men in the US are living with advanced stage prostate cancer presenting a potential market opportunity of more than US $4Bn annually. Antev planned Phase 2b Study Design in Advanced Prostate Cancer Open label study in 40 men with advanced prostate cancer suitable for ADT. The participants shall receive a loading dose of 180mg IM plus x2 180mg SC (total 540mg), followed by x2 180mg (360mg) SC day 29 and every 6 weeks. The total duration of the treatment is 22 weeks. Primary endpoint is to confirm castration rate by day 29, sustaining to day 155, probability greater than 90%. ... Read the full article here. ----- No. 3 MDCX Potential Catalyst - A Pair Of Analyst Targets Suggest Major Upside Potential (Triple-Digit!). Check out what MarketBeat is reporting: As of Thursday's close, MDCX had two different analyst targets pointing to a significant amount of upside potential. Jason Kolbert of D. Boral Capital has given MDCX a $27 target representing a potential upside over 690% from last week's close. Additionally, Jason McCarthy of Maxim Group has provided a $20 target suggesting 490+% potential upside from last week's close. Could (Nasdaq: MDCX) be undervalued from current chart levels? ----- No. 4 MDCX Potential Catalyst - Medicus Adds New COO As Company Ramps Up Active Engagements Across 3 Continents. Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer Philadelphia, Pennsylvania--(Newsfile Corp. - June 23, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the appointment of Andrew Smith as Chief Operating Officer. Andrew joins Medicus with over three decades of experience and is an accomplished C-suite professional with a successful track record as a leader in asset management and financial operations. Andrew, most recently, was the Chief Executive of SR Asset Management (SRAM) until its sale in 2024. Before joining SRAM in 2017, he was the Co-Head of Americas and Chief Operating Officer of Aberdeen Asset Management Inc. At Aberdeen, he held various roles including Chief Compliance Officer for their North American Closed End Funds as well as Chief Financial Officer and Chief Operating Officer for Aberdeen in the Americas. He currently sits on the board of HazelTree Fund Services and is an advisor to Code Registry. Andrew holds an Executive MBA from INSEAD in Fountainebleau and received an HND in Accounting from Glasgow College of Commerce, Scotland. "We are delighted to welcome Andrew to the leadership team," stated Dr. Raza Bokhari, Executive Chairman and CEO. "Andrew's experience and expertise is very relevant and timely, as we expand our business and clinical development operations with active engagements in three continents." ... Read the full article here. ----- No. 5 MDCX Potential Catalyst - A Potential $250Mn Market Could Be Nearing Disruption As Medicus Announces Submission To The FDA. Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses Company Is Advancing Use of Novel Doxorubicin-containing Microneedle Array (D-MNA) Patch in Veterinary Oncology as an Orphan Drug Philadelphia, Pennsylvania--(Newsfile Corp. - June 9, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce submission of a comprehensive product development plan to treat external squamous cell carcinoma (SCC) under Investigational New Animal Drug (INAD File No.013880). The Company, in December 2024, received a Minor Use in Major Species Designation (MUMS) for its dissolvable Doxorubin-containing microneedle array (D-MNA) to treat external squamous cell carcinoma (SCC) in horses. The product development plan is designed to seek concurrence of the FDA under MUMS designation. MUMS is a status similar to Orphan Drug status for human drugs. It entitles the Company to an extended 7-year period of exclusive marketing following approval or conditional approval, provided that the Company meets all requirements for maintaining the designation. Doxorubicin-containing microneedle array (D-MNA) is a patent protected dissolvable transdermal patch with cellulose based microneedle arrays that are tip-loaded with doxorubicin. After application, the microneedles function by penetrating the strateum corneum layer of the skin, create a temporary microchannel, penetrate the tumor, dissolve and release doxorubicin into the target tumor, and eradicate the cancer cells. "In Veterinary Medicine, where there are only a handful of approved oncology drugs, we believe developing a non-invasive treatment for equine SCC represents an untapped and unmet market opp. potentially in the range of $250Mn," stated Dr. Raza Bokhari, Executive Chairman & CEO. "The submission to the FDA of a novel product development program may provide us a first mover advantage and sets the stage to consider other companion animal species and types of cancer." ... Read the full article here. ----- (Nasdaq: MDCX) Recap - These 5 Potential Breakout Catalysts Lead The Way No. 1 - A Low Float Could Create The Environment For Heightened Volatility. No. 2 - A Definitive Agreement Moves Medicus Pharma A Step Closer To A Game-Changing Acquisition. No. 3 - A Pair Of Analyst Targets Suggest Major Upside Potential (Triple-Digit!). No. 4 - Medicus Adds New COO As Company Ramps Up Active Engagements Across 3 Continents. No. 5 - A Potential $250Mn Market Could Be Nearing Disruption As Medicus Announces Submission To The FDA. ----- Coverage is officially initiated on Medicus Pharma Ltd. (Nasdaq: MDCX). Be on the lookout for updates coming shortly. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 07/06/2025 and ending on 07/11/2025 to publicly disseminate information about (MDCX:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (MDCX:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/mdcx-ozsfc/#details

SWN Media | 160 W. Camino Real Unit 886 | Boca Raton, FL 33432 US Unsubscribe | Update Profile | Constant Contact Data Notice